Statistics for Prelude Therapeutics (id:7949 PRLD)

Valuation metrics

Market cap

63.29M

Enterprise value

-72,199,552.00

Trailing P/E (ttm)

-0.47

Forward P/E

-0.76

PEG ratio

-0.76

Price/Sales (ttm)

21.10

Price/Book (mrq)

0.40

Enterprise Value/Revenue

-24.07

Enterprise Value/EBITDA

0.51

Overview

Shares outstanding

42.18M

Float

13.74M

Shares short

2.49M

% Held by insiders

0.09%

% Held by institutions

0.95%

Average volume (10 days)

485.37K

Average volume (90 days)

Price summary

52-Week low

0.93

52-Week high

6.80

52-Week change

-242.47%

Beta

1.55

50-Day moving average

2.37

200-Day moving average

3.87

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-1,145.87%

Operational effectiveness

Return on assets

-39.29%

Return on equity

-66.64%

Income statement

Revenue (ttm)

0.04

Revenue per share (ttm)

0.04

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-141,648,000.00

Net income to common (ttm)

-131,517,000.00

Diluted EPS (ttm)

-1.77

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

153.63M

Total cash per share (mrq)

2.79

Total debt (mrq)

18.14M

Total Debt/Equity (mrq)

11.59

Current ratio (mrq)

703.70%

Book value per share (mrq)

2.84

Cash flow

Cash flow statement

-105,722,000.00

Levered free cash flow (LFCF)

-61,550,752.00